Subscribe to RSS
DOI: 10.1055/s-0029-1225285
© Georg Thieme Verlag KG Stuttgart · New York
Gastroenterologie 2009
Gastroenterology 2009Publication History
Publication Date:
10 June 2009 (online)
Was ist neu?
-
Endoskopie: Neue Verfahren zur Dünndarmenteroskopie und Radiofrequenzablation bei Barrett-Ösophagus.
-
Ösophaguserkrankungen: Prävalenz der eosinophile Ösophagitis steigt.
-
Reizdarmsyndrom: Neue Therapieansätze
-
Chronisch entzündliche Darmerkrankungen: Langzeittherapie und postoperative Rezidivprophylaxe mit Azathioprin, Karzinomrisiko bei Morbus Crohn.
-
Gastrointestinale Onkologie: Therapie des Pankreaskarzinoms bleibt Herausforderung; Rauchen als Risikofaktor für viele gastrointestinale Karzinome, Kolonandemone und Pankreatitis.
Literatur
- 1 Akerman P A, Cantero D, Avila J. et al . The spiral enteroscopy experience in 101 consecutive patients: safty and efficacy using the Discovery SB. Gastrointest Endosc. 2008; 67 AB92-93
- 2 Bechtler M, Eickhoff A, Riemann J F. Intervallkarzinom und mögliche Ursachen. Dtsch Med Wochenschr. 2008; 133 2458-2462
- 3 Baxter N N, Goldwasser M A, Paszat L F. et al . Association of Colonoscopy and Death From Colorectal Cancer: A Population-Based, Case–Control Study. Ann Intern Med. 2009; 150 1-8
- 4 Bokemeyer C, Bondarenko I, Makhson A. et al . Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009; 10,27 663-671
- 5 Botteri E, Iodice S, Bagnardi V. et al . Smoking and colorectal cancer: a meta-analysis. JAMA. 2008; 300 2765-2778
- 6 Botteri E, Iodice S, Raimondi S. et al . Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology. 2008; 134 388-395
- 7 Buscaglia J M, Dunbar K B, Okolo P I. et al . The spiral enteroscopy training initiative: results of a prospective study evaluating the Discovery SB overtube device during small bowel enteroscopy. Endoscopy. 2009; 41 194-199
- 8 D’Haens G R, Vermeire S, van Assche G. et al . Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology. 2008; 135 1123-1129
- 9 Di Nicolantonio F, Martini M, Molinari F. et al . Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26 5705-5012
- 10 Domenech E, Manosa M, Bernal I. et al . Impact of azathioprine on the prevention of postoperative Crohn’s disease recurrence: Results of a prospective, observational, long-term follow-up study. Inflamm Bowel Dis. 2008; 14 508-513
- 11 Fleischer D E, Overholt B F, Sharma V K. et al . Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2,5-year follow-up. Gastrointest Endosc. 2008; 68 867-876
- 12 Friedman S, Rubin P H, Bodian C. et al . Screening and surveillance colonoscopy in chronic Crohn’s colitis: Results of a surveillance program spanning 25 years. Clin Gastroenterol Hepatol. 2008; 6 993-998
- 13 Gupte A R, Draganov P V. Eosinophilic esophagitis. World J Gastroenterol. 2009; 15 17-24
- 14 Hartmann D, Eickhoff A, Tamm B. et al . Balloon-assisted enteroscopy using a single-balloon technique. Endoscopy. 2007; 39 E276
- 15 Heresbach D, Barrioz T, Lapalus M G. et al . Miss rate for colorectal neoplastic polyps: a prospective multicenter study of back-to-back video colonoscopies. Endoscopy. 2008; 40 284-290
- 16 Imperiale T F, Glowinski E A, Lin-Cooper C. et al . Five-year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med. 2008; 359 1218-1224
- 17 Iodice S, Gandini S, Maisonneuve P. et al . Tobacco and the risk of pancreatic cancer: A review and metaanalysis. Langenbecks Arch Surg. 2008; 393 535-545
- 18 Johanson J F, Drossman D A, Panas R. et al . Phase II study of lubiprostone for irritable bowel syndrome with constipation. Aliement Pharmacol Ther. 2008; 27 685-696
- 19 Kapel R C, Miller J K, Torres C. et al . Eosinophilic esophagitis: Aprevalent disease in the United States that affects all age groups. Gastroenterology. 2008; 134 1316-1321
- 20 Kindler H L, Gangadhar T, Karrison T. et al . Final analysis of a randomized phase II study of bevacizumab (b) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients with advanced pancreatic cancer. J Clin Oncol. 2008; 26 4502
- 21 Kullmann F, Hollerbach S, Dollinger M M. et al . Cetuximab plus gemcitabin/oxaliplatin (GEMOXCET) in first line metastatic pancreatic cancer: a multicenter phase II study. Br J Cancer. 2009; 100 1032-1036
- 22 Liang P S, Chen T Y, Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer. 2009; 124 2406-2415
- 23 Lindkvist B, Appelros S, Manjer J. et al . A prospective cohort study of smoking in acute pancreatitis. Pancreatology. 2008; 8 63-70
- 24 Martínez M E, Baron J A, Lieberman D A. et al . A Pooled Analysis of Advanced Colorectal Neoplasia Diagnoses After Colonoscopic Polypectomy. Gastroenterology. 2009; 136 832-841
- 25 Neuhaus P, Riess H, Post S. et al . CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol. 2008; 26 214s; abstr LBA4504
- 26 Picozzi V J, Abrams R A, Traverso L W. et al . ACOSOG Z05031: Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5-FU, and alpha-interferon. J Clin Oncol. 2008; 26 4505
- 27 Pouw R E, Sharma V K, Bergman J J. et al . Radiofrequency ablation for total Barrett’s eradication: a description of the endoscopic technique, its clinical results and future prospects. Endoscopy. 2008; 40 1033-1040
- 28 Sargent D J, Marsoni S, Thibodeau S N. et al . Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol. 2008; 26 180s; abstr 4008
- 29 Schorr F, Riemann J F. Gastroenterologie 2008. Dtsch Med Wochenschr. 2008; 133 1362-1365
- 30 Tol J, Koopman M, Cats A. et al . Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009; 360 563-572
- 31 Treton X, Bouhnik Y, Mary J Y. et al . Azathioprine withdrawal in patients with Crohn’s disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol. 2009; 7 80-85
- 32 Tsujikawa T, Saiton Y, Andoh A. et al . Novel single-ballon enteroscopy for diagnosis and treatment of the small intestine: preliminary experiences. Endoscopy. 2008; 40 11-15
- 33 Van Cutsem E, Lang I, D’Haens G. et al . KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol. 2008; 26 5s; abstr.
- 34 Wilhelm S M, Brubaker C M, Varcak E A. et al . Effectiveness of probiotics in the treatment of irritable bowel syndrome. Pharmacotherapy. 2008; 28 496-505
-
35 Zijdenbos I L, de Wit N J, van
der Heijden G J. et al .Cochrane
Database Syst Rev 2009 CD006442
Dr. med. Friedrich Schorr
Medizinische Klinik C, Klinikum Ludwigshafen
Bremserstrasse 79
67063 Ludwigshafen am Rhein
Phone: 0621/5034104
Fax: 0621/5034114
Email: schorrf@klilu.de